Long-term outcomes of systemic corticosteroid-sparing immunomodulatory therapy for Birdshot Retinochoroidopathy

ABSTRACT

Purpose

To report the visual prognosis, electroretinography (ERG) and perimetry outcomes of systemic corticosteroid-sparing immunomodulatory treatment (IMT) for birdshot retinochoroidopathy (BSRC).

Methods

Retrospective non-comparative case series of 132 patients (264 eyes) with BSRC treated with IMT from Massachusetts Eye Research and Surgery Institution.

Results

The average follow-up time was 60.1 months. After one year on IMT, 39.4% showed no clinically active inflammation. After 5 years of IMT, 78.0% had no signs of clinical inflammation. No significant differences were observed on best-corrected visual acuity (BCVA), ERG parameters, and perimetry parameters between baseline and subsequent visits on IMT.

Conclusion

Long-term systemic corticosteroid-sparing IMT was associated with a low rate of BSRC disease exacerbation. While differences were seen on testing parameters, they were not consistent trends and difference were attributed to variability of testing or fluctuation of inflammation that may be expected in the course of the disease.

Keywords:

• Birdshot retinochoroidopathy
• electroretinography
• immunomodulatory therapy
• perimetry
• remission

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Summary statement

Long-term systemic corticosteroid-sparing immunomodulatory treatment is associated with a low rate of exacerbation in patients with birdshot retinochoroidopathy. Appropriate treatment and rigorous monitoring may offer hope of achieving remission and maintaining both retinal function and vision.

Financial Disclosure

The authors have no proprietary or commercial interest in any materials discussed in this article. No funding sources exist for this original manuscript.